The impact of PD-1 immune checkpoint therapy prompts exploration of other strategies to downregulate PD-1 for cancer therapy. We previously showed that the serine/threonine kinase, glycogen synthase kinase GSK-3 / , is a central regulator of PD-1 transcription in CD8+ T cells. Here, we show that the use of small molecule inhibitors of GSK-3 / (GSK-3i) to reduce pcdc1 (PD-1) transcription and expression was as effective as anti-PD-1 and PDL-1 blocking antibodies in the control of B16 melanoma, or EL4 lymphoma, in primary tumor and metastatic settings. Further, the conditional genetic deletion of GSK-3 / reduced PD-1 expression on CD8+ T cells, and limited B16 pulmonary metastasis to the same degree as PD-1 gene deficiency. In each model, GSK-3i inhibited PD-1 expression on tumor infiltrating lymphocytes (TILs), while increasing Tbx21 (T-bet) transcription, and the expression of 
Introduction
The co-receptor programmed cell death 1 (PD-1; PDCD1) is a member of the B7 gene family that negatively regulates T-cell function (1) (2) (3) . PD-1 is expressed in response to T-cell activation and contributes to the exhaustion of CD8 + T-cells during chronic infections (4, 5) . The co-receptor binds to ligands, programmed cell death ligand 1 and 2 (PD-L1/L2), on lymphoid and non-lymphoid cells (6) (7) (8) . Immune checkpoint blockade with anti-PD-1 or anti-PD-L1 has proven successful in the treatment of human cancers, either alone or in combination with anti-CTLA-4 (9,10). PD-1 expression on tumor-infiltrating CD8 + T-cells correlates with impaired effector cell function (2,11),
while PD-L1 expression on tumors can facilitate escape from the host immune system (3), and can serve as a prognostic factor (12) . Recent evidence indicates that recovery of responses from anti-PD-1 blockade depends on the related co-receptor (13) (14) (15) .
The nature of the intracellular signaling pathways that regulate PD-1 expression on T-cells has been the subject of much interest. Pdcd1 expression can be positively and negatively regulated by different transcription factors such as nuclear factor of activated T-cells (NFAT), Forkhead box protein O1 (FoxO1), Notch, activator protein 1 (AP1), and Blimp1 (B-lymphocyte maturation protein 1) (16) (17) (18) (19) . Despite this, the identity of the upstream signaling event(s) that control PD-1 expression has been unclear. We and others previously showed that T-cells are activated by protein-tyrosine kinases p56 lck and ZAP-70 (20, 21) . p56 lck binds to co-receptors CD4 and CD8 (22) (23) (24) and phosphorylates immune receptor activation motifs (ITAMs) needed for ZAP-70 recruitment to the TcR-CD3 complex (20, 23, 25) . By contrast, glycogen synthase kinase 3 (GSK-3) is a serine/threonine kinase that is active in resting T-cells, and becomes inactivated with T-cell activation (26, 27) . Differentially regulated isoforms of GSK-3 and differ in their N-and C-terminal sequences and can influence pathways initiated by diverse stimuli. The inactivation of GSK-3 can be mediated by several upstream kinases including protein kinase B (PKB/AKT). In CD4 + T-cells, GSK-3 promotes the exit of NFAT from the nucleus (28, 29) . TCR and CD28 ligation phosphorylates and inactivates GSK-3 (30) (31) (32) , while expression of active GSK-3 inhibits the proliferation of T-cells 
Materials and Methods

Mice and cells.
C57/Bl6 mice were used alongside OT-1 Tg and Rag2 knockout mice. Spleen cells were treated with a hypotonic buffer with 0.15M NH4CL, 10mM KHCO3 and 0.1mM EDTA, pH 7.2 to eliminate red blood cells before suspension in RPMI 1640 medium supplemented with 10% FCS, 50uM beta-mercaptoethanol, sodium pyruvate, 2 mM L-glutamine, 100 U/ml penicillin and streptomycin (GIBCO). T cells were isolated from tumor infiltrating cells, spleen and lymph node samples by use of T cell purification columns (R&D Systems). In some cases, whole lymphocyte samples were used for flow cytometry to determine PD-1 expression in other cell types. Cells included B16 F10 melanoma and EL4 lymphoma cells (obtained from the ATCC). Each cell line was grown to achieve adequate numbers for freezing, followed by repeated thawing for use in the described experiments. The length and time between thawing and use in experiments was on average 3-4 weeks. The cell lines were authenticated by means cell surface staining and flow cytometry for characteristic markers and by their growth properties as described in the literature. 
Antibodies and reagents.
The following antibodies were used in experiments; Anti-CD3 (2C11), anti-PD-1 (CD279, J43) and anti-CTLA-4 (9H10) (BioXCell); PD-L1 (E1L3N; Cell Signaling Technology), anti-Granzyme B and anti-T-bet (Abcam plc); anti-GSK-3 / , CD279 (clone EH12.2H7) coupled FITC and mouse IgG1 
Quantitative real-time polymerase chain reaction (PCR).
Single-strand cDNA was synthesized with an RT-PCR kit (Qiagen) according to the manufacturer's instructions. Reverse transcription was performed using the RNA polymerase chain reaction (PCR) core kit (Applied Biosystems). Quantitative real-time PCR used SYBR green technology (Roche) on cDNA generated from the reverse transcription of purified RNA. After preamplification (95°C for 2 min), the PCRs were amplified for 40 cycles (95°C for 15s and 60°C for 60s) in a sequence detection system (PE Prism 7000; Perkin-Elmer Applied Biosystems). The exponential phase, linear phase and plateau phase of PCR amplification were carefully monitored to ensure a measurement of real time transcription (33) . mRNA expression was normalized against GAPDH expression using the standard curve method. PD-1-FW, 5-CCGCCTTCTGTAATGGTTTGA-3; PD-1-RV, 5-GGGCAGCTGTATGATCTGGAA-3; Tbet-FW, 5-GATCGTCCTGCAGTCTCTCC-3; Tbet-RW, 5-AACTGTGTTCCCGAGGT GTC-3; GAPDH-FW, 5-CAACAGCAACTCCCACTCTTC-3; GAPDH-
RW, 5-GGTCCAGGGTT TCTTACTCCTT-3
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Microarray data
There is no microarray data in the paper.
Adoptive transfer of in vitro generated cytolytic T-cells (CTLs).
In vitro generated T-cells were injected into mice with 7 day established EL4 tumors. For this, OT-1
CTLs were generated in vitro as previously described (36) . Primary mouse T cells were isolated using T-cell purification columns (R&D Systems). OVA-specific CD8 + cytolytic T-cells were generated by incubating OT-I splenocytes with SIINFEKL peptide of OVA (OVA 257-264 ) at 10 ng/mL for 5-7 days. Isolated T-cells (10 5 cells) were injected i.v. into mice with established EL4 tumors that had been intra-dermally injected into mice 7 days before cell transfer.
Intradermal tumor establishment.
EL4 or B16 tumor cells were taken from the log phase of in vitro growth (approx.. 70% confluency).
In some cases where stated, cells were pulsed with OVA peptide for 1hr at 37 o C). were harvested as indicated, either on day 10 or when the tumor reached a maximum diameter of 12mm. PCR and flow cytometry were performed.
Isolation of tumor infiltrating lymphocytes (TILs).
Solid tumors or nodules from lungs were harvested from mice at the time indicated. Tissue was disrupted using a blade and then incubated in HBSS solution containing 200units/ml of collagenase at 37 o C for 2 hrs. Tissue was then passed through a strainer and cells collected and layered onto ficoll before centrifugation. Tumor infiltrating cells were then collected from the lymphocyte layer.
Statistical analysis.
The mean and SE of each treatment group were calculated for all experiments. The number of samples is indicated in the figure legends. Unpaired Student's t tests or ANOVA tests were performed using the InStat 3.0 software (GraphPad). In certain instances, statistics were done using 2-way ANOVA, or by non-parametric Mann Whitney at each time point. * P < 0.05, ** P < 0.01, *** P < 0.001.
Results
GSK-3 inhibits the growth of intravenous and intradermal injected tumors.
To assess whether the down-regulation of PD-1 by GSK-3 inhibition (GSK-3i) was effective in limiting tumor growth, B16 tumor cells were injected intravenously into C57/b6 mice with the GSK-3 inhibitor SB415286 and/or anti-PD-1 (Fig. 1A) . The optimal dose of SB415286 and anti-PD-1 established in this model was 200ug and 100ug/injection/mouse, respectively. The SMI or antibody was administered every two days following the injection of tumor, followed by a harvest of lungs on day 14 and an assessment of numbers of B16 nodules. GSK-3 inhibitor SB415286 reduced the number of B16 spots from a mean of 145 to 60 (i.e. >55% inhibition). This effect was comparable to anti-PD1 which showed a mean of 70 spots (i.e. >50% inhibition). Further, the combination of SB415286 and anti-PD-1 had the same effect as SB415286 and anti-PD-1 individually (n=6). Flow cytometry confirmed that GSK-3i reduced PD-1 expression on T-cells from the tumor (i.e. tumor infiltrating (TILs), spleen and draining lymph nodes (Fig. 1B) . By contrast, no effect on the expression of other receptors such as CD3, CD8, CD44, CD62L, CD25 and CD69 was observed (Fig. 1D) . These data showed that the down-regulation of PD-1 with a small molecule inhibitor of GSK-3 can be as effective as anti-PD-1 in the control of B16 pulmonary metastasis in mice.
We also examined the effect of SB415286 doses on the growth of B16 cells tagged with luciferase ( Fig. 1E) . At day 14, mice were injected intraperitoneally with luciferin and scanned by IVIS Lumina imaging. SB416286 reduced the luciferase signal at 100 and 200ug/mouse, the dose of 200ug being more effective (left panels). In terms of T-cell subsets, both doses reduced PD-1
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on October (Fig. 2B) . Intriguingly, the tumor growth in GSK-3 / -/-mice was reduced to a similar extent as seen in Pdcd1-/-mice (i.e. from 110 spots to <10 in both sets of mice) (Fig. 2C) . Further, the injection of anti-PD-1 in GSK-3 / -/-mice had no further effect on the number of nodules in lungs (Fig. 2B, upper inset) . Conversely, the injection of SB415286, or another GSK-3 inhibitor, AZ1080 in Pdcd1-/-mice had no additional effect in reducing the number of nodules (Fig. 2C, upper inset) . Overall, the data showed that GSK-3 inhibitor preferentially down- anti-PD-1 had no further effect on tumor growth in GSK-3 / -/-mice supported the notion that GSK-3 inhibition operated to limit tumor growth primarily via the down-regulation of anti-PD-1.
To further exclude that SB415286 had a direct effect on tumor cells, the SMI was injected into Rag2-/-mice (missing B and T-cells) with the B16 tumor (Fig. 2D) . Under this condition, SB415286 had no effect on limiting tumor growth. In addition, carboxyfluorescein succinimidyl ester (CFSE) labelled B16 cells were co-cultured of SB415286 in vitro over 5 days and assessed for differences.
SB415286 had no obvious effect on the growth of B16 cells (Supplementary Fig. S2 ). Taken together, these data was most consistent with the interpretation that protective effects of GSK-3i was due primarily to an effect on CD8 + T-cells.
We next also assessed whether the SMI SB415286 could affect PD-1 expression on human Fig. S3 ). Human CD4+ CD8+ T cells isolated from human peripheral blood were stimulated with anti-CD3/CD28 for 72hs prior to resting overnight and then incubated with SB415286 for various times and stained by flow cytometry for PD-1 expression. The SMI reduced the % of cells expressing PD-1 by >55% and the mean fluorescent intensity (MFI) for expression by >65% for cells when assayed at 48 hours (left upper and lower panels). Lesser inhibition was also apparent at >96 hours. See examples in right panels at 10min, 24 and 48 hours (right panel). As a control, the expression of CD3, CD4 and CD8 was unaffected. These data confirm that GSK-3i can be used to down-regulate PD-1 on CD3+CD8+ human T-cells.
T-cells (Supplementary
SB415286 and anti-PD-1 had similar effects on the growth of more established B16 pulmonary metastases in mice (Fig. 3A) . B16 tumor cells were injected intravenously and left for 7 days before beginning treatment. Lungs were harvested on day 19, and assessed for B16 nodules.
Due to the extended time, non-treated animals showed larger nodules than seen in the previous experiments. Despite this, injection of mice with either SB415286 and anti-PD-1 greatly reduced the number of nodules from 135 to 5-20. Both reagents also reduced the size of the remaining nodules from a mean of 3 to 0.05mm in diameter. Further, the combined injection of SB415286 and anti-PD-1 reduced the number of spots to the same extent as each individual treatment (i.e. 5-10).
Research. As a control, qPCR measurements confirmed the reduction in pcdc1 transcription, with a concurrent increase in Tbx21 transcription in splenic T-cells (Fig. 3B) . This reduction in PD-1 expression was confirmed by flow cytometry where we observed that SB415286 or combined therapy reduced PD-1 expression in T-cells from spleen and TILs (Fig. 3C) . Further, this reduction in expression correlated with an increase in Lamp1 and GZMB expressing CD8 + TILs (Fig. 3D) .
We next investigated whether GSK-3 inactivation was also as effective as anti-PD-1 checkpoint blockade in the control of the growth of solid B16 tumors. For this, B16 cells were injected intra-dermally, followed by intra-peritoneal injections of either SB415286 or anti-PD-1 (Fig.   4A ). We found that SB415286, anti-PD-1 and the combination slowed tumor growth such that 10mm sized tumors were not seen until days 19-22, rather than day 14 in untreated mice. Further, SB415286 or anti-PD-1 increased overall survival to the same general extent, as seen in the Kaplan-Meier survival plot with a 40-50% survival at day 30 (Fig. 4B) . As a control, qPCR of isolated spleen T-cells showed a marked decrease in pdcd1 transcription, while increasing the transcription of Tbx21 (Fig. 4C) . Flow cytometry also showed a decrease in PD-1 expression in Tcells from the spleen and extracted TILs (n=5) (Fig. 4D) . Reduced Pdcd1 and increased Tbx21 transcription was also observed in TILs (Fig. 4E) . Lastly, both SB415286 and combination therapy increased the numbers of CD107a + GZMB + CD8 + cells indicative of the increased presence of more effective killer T-cells (Fig. 4F) . There was no significant difference between the number of CD107a + GZMB + CD8 + cells with SB415286 versus SB415286 and anti-PD-1.
We also assessed the effect of GSK-3 inactivation on immune cell rejection of another tumor model, EL4 lymphoma cells (Fig. 5) . Priming of OT-1 OVA-specific T cells with SIINFEKL peptide of OVA (OVA 257-264 ) produces a specific CTL response against tumor targets (37). EL4 cells were pretreated with 0, 2, 5 and 10ug of OVA peptide, and washed, prior to injection. EL4 cells not exposed to peptide were injected into the left flank of OT-1 Tg mice, while those exposed to peptide were injected into the right flank. SB415286 was injected intra-peritoneally on day 0, and tumor growth
was then monitored over 10 days before harvesting (Fig. 5A, upper panel) . Tumor size was reduced especially with 5 and 10ug OVA peptide; however, tumors were still evident at all peptide concentrations (lower panels). By contrast, in 4/7 experiments, SB415286 treatment resulted in a complete loss of tumor mass at all peptide concentrations in > 80% of mice. This remarkable tumor clearance was observed in mice of different ages, 4-6 weeks (Supplementary Fig. S4A ), [6] [7] [8] [9] [10] weeks (Supplementary Fig. S4B ) and 6 months (Supplementary Fig. S4C) . As a control, real time PCR of splenic T-cells confirmed SB415286 in vivo injection inhibited pcdc1 transcription, while increasing Tbx21 transcription (Fig. 5B) . Fig. S5 ).
In another approach, we assessed PD-1 blockade using a blocking antibody to the PD-1 ligand (PD-L1) (Fig. 5D) We then compared the effect of GSK-3 inactivation versus anti-PD-1 on EL4 solid tumors in the absence of OVA peptide (Fig. 6) . This required co-injections of SB415286 and/or anti-PD-1 as depicted (Fig. 6A) and an assessment of tumor growth over a longer period of 40 days. EL4 tumors grew to 10mm by day 5 in untreated mice, which was prolonged to day 12 in SB41528 and anti-PD-1-treated mice (lower panel). The tumor completely regressed in one to three mice by day 18 with anti-PD-1, or the combination of SB41528 and anti-PD-1. The cooperative effect of combination therapy was also reflected in survival (Fig. 6B) . While untreated mice died by 11 days, 50% of mice on combined therapy remained alive by 40 days as shown in the Kaplan-Meier survival plot. Flow cytometry of T-cells isolated from the spleens, draining lymph nodes and TILs demonstrated lower expression levels of PD-1 (Fig. 6C) . This was confirmed with PCR demonstrating a reduction in Pdcd1 and an increase in Tbx21 (Fig. 6D) .
To determine the duration of the effect of SB415286, PD-1 expression was monitored in mice co-injected with EL-4 tumors and a single injection of the drug (Supplementary Fig. S6 ). Mice were sacrificed at various times and PD-1 expression on spleen CD3+CD8+ T-cells was assessed by flow cytometry. The effects on PD-1 expression on CD3+CD8+ T-cells was sustained until 7-10 days (i.e. 57% suppression at day 5; 42% at day 7) with expression returning to control levels from day 10-14 (i.e. 22% suppression at day 10 and 7% at day 14). These data indicate that the effects of SB415286 was sustained for over 7-10 days.
Lastly, we tested whether pre-treatment of T-cells ex vivo with SB415286 provided protection (Fig. 7) . EL4 cells were intra-dermally injected into mice for 7 days followed by the transfer of OT-1
CTLs that had been cultured in vitro for 7 days in the absence or presence of OVA peptide plus the SMI SB415286 or anti-PD-1. The transfer of cells without any SB415286 or anti-PD-1 pre-treatment delayed the onset of growth at all peptide concentrations (Fig. 7A) . However, pre-treatment with showed the expected decrease in pcdc1 transcription while increasing the transcription of Tbx21 (Fig. 7B) . Flow cytometry prior to transfer confirmed the reduction in PD-1 expression at different OVA concentrations (Fig. 7C) . These data showed that the efficacy of GSK-3 inhibition was the result of a direct effect on T-cells, and that the pre-treatment of T-cells ex vivo with either anti-PD-1 or SB415286 provided protection against tumor growth. 
Discussion
Immune checkpoint blockade with anti-PD-1 or anti-PD-L1 has proven to be a highly promising treatment of human cancers, either alone or in combination with other reagents such as anti-CTLA-4 (2,9,10). However, only a minority of patients is responsive to this therapy, and there is a need to find alternate ways to complement present approaches. We previously showed that the kinase GSK-3 / is a central regulator of PD-1 expression and that small molecule inhibitors of GSK-3 (GSK3i) are effective in promoting viral clearance (33) . In this paper, we have shown that GSK-3i inhibition of pcdc1 (PD-1) transcription with a small molecule inhibitor (i.e. SB415286) is as effective as anti-PD-1 and PDL-1 blocking antibodies in the control of B16 and EL-4 tumor growth.
Our findings identify a potential alternate approach using small molecule inhibition of PD-1 expression in cancer therapy. Occasionally, we observed some cooperation between anti-PD-1 and GSK-3i in the EL4 model, and therefore, we cannot exclude that future work will show cooperativity dependent on the tumor model.
Lastly, we found that the ex vivo pre-treatment of CTLs followed by adoptive cell transfer was effective in the control of tumor growth. As in the other models, SB415286 and anti-PD-1 delayed the onset of growth to the same extent. This experiment confirmed that the protective effect of GSK- 
3 on tumor growth was due to an effect on the function of T-cells. Combination therapy did not provide an obvious improvement, supporting the notion that SB415286 was acting to inhibit tumor growth primarily by down-regulating the expression of PD-1. GSK-3 SMIs may therefore have application to cell therapy, potentially to improve chimeric antigen receptor (CAR) therapy (43).
Overall, there are potential advantages and disadvantages to the use of the GSK-3 SMI versus anti-PD-1 antibody therapies. Anti-PD-1 therapy is expensive and associated with adverse effects such as fatigue, rash and possible autoimmune complications such as colitis. Although we cannot exclude these inflammatory effects with the use of GSK-3 inhibitors, we have seen no evidence of autoimmunity with SMIs or in the GSK-3 / -/-mice over 2 years. Further, the use of many GSK-3 inhibitors is no longer restricted by patent coverage (27) , and SMI inhibition offers the advantage of more accurate dosing, lower cost and the potential of oral administration. Importantly, PD-1 expression on both murine and human T-cells were down-regulated by GSK-3i.
The potential disadvantage of GSK-3 inactivation is a possible direct effect on the function of other host cells or the tumor itself. However, lithium chloride, an inhibitor of GSK-3, has been used for decades for the treatment of bipolar disease without a reported increase in tumor frequency. The dose of SB415286 inhibitor (200ug per 20g mouse) in our study was roughly comparable to the dose of another inhibitor Tideglusib used in a phase 2 oral study (800mg in a 80kg patient) to treat progressive supranuclear palsy (35) . Further, we showed that the effects of GSK-3 SMIs are durable such that a single dose injection of SB415286 down-regulated PD-1 for 10-14 days.
Although, we failed to see any effect of SB415286 on the growth of B16 melanoma cells, GSK-3 inhibition has been reported to directly inhibit the growth of multiple myeloma, neuroblastoma, hepatoma and prostate tumors (44-48). It is therefore possible that, in some instances, GSK-3 inhibitors might directly inhibit the growth of some tumors. Despite these possibilities, the major effect of GSK-3i in our studies was amplify the ability of the immune system to react against tumor growth as shown by the effect of ex vivo treated T-cells in adoptive cell therapy as well as by the 
